Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

PURPOSE: Balancing disease control and toxicity from chemotherapy and radiotherapy (RT) when treating early-stage classical Hodgkin lymphoma (cHL) is important. Available data on long-term toxicity after RT for cHL mostly refer to RT techniques no longer in use. We aimed to describe long-term toxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Lagerlöf, Ingemar, Fohlin, Helena, Enblad, Gunilla, Glimelius, Bengt, Goldkuhl, Christina, Palma, Marzia, Åkesson, Lisa, Glimelius, Ingrid, Molin, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061145/
https://www.ncbi.nlm.nih.gov/pubmed/35077204
http://dx.doi.org/10.1200/JCO.21.02407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061145/
https://www.ncbi.nlm.nih.gov/pubmed/35077204
http://dx.doi.org/10.1200/JCO.21.02407

Ejemplares similares